CONFERENCE UPDATE: CROI 2022
54-WEEK results of lenacapavir in treatment-naïve patients with HIV: Calibrate study
5-year outcomes of B/F/TAF in treatment-naïve adults
Bictegravir (B; BIC), emtricitabine (F; FTC), and tenofovir alafenamide (TAF) or B/F/TAF is a single-tablet coformulation that is recommended for people living with human immunodeficiency virus (HIV).1 It can be taken once daily without food restrictions, and has a high barrier to resistance with a favorable drug-drug interaction profile.1
This presentation reported the 5-year treatment outcomes of B/F/TAF in treatment-naïve adults. There were 2 randomized, double-blind phase 3 studies of B/F/TAF in treatment-naïve adults, namely study 1489 [B/F/TAF vs. dolutegravir/abacavir/lamivudine (DTG/ABC/3TC)] and study 1490 (B/F/TAF vs. DTG+F/TAF).1 After 144 weeks of blinded treatments, subjects were offered a continuation of B/F/TAF for 96 weeks as part of an open-label extension study.1 Efficacy was assessed as proportion with HIV-1 (ribonucleic acid) RNA <50 copies/mL at each visit after B/F/TAF using missing=excluded (M=E) analysis, safety and laboratory results.1
